

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited
諾輝健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6606)

CLARIFICATION ANNOUNCEMENT

NEW HORIZON HEALTH'S STATEMENT ON SHORT SELLER REPORT

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis.

On August 16, 2023, a report from a self-proclaimed short seller made numerous inaccurate, unfounded and misleading allegations about the Company designed to negatively impact the Company's share price for the short seller's own benefit. The allegations in the report are blatantly false.

From its inception, the Company has operated with an unwavering commitment to compliance, ethics, and integrity. The Company remains focused on its mission to advance the innovation and accelerate the adoption of cancer screening technologies in China and globally.

The Company also confirms that the Company does not currently possess any inside information that is required to be published pursuant to Rule 13.09 of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited and under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

Information on the Company

The Company is a commercial stage biotech company principally engaged in developing and commercializing innovative cancer screening products to address significant unmet medical needs in the cancer screening industry in China.

By order of the Board
New Horizon Health Limited
Mr. YeQing ZHU
Chairman

Hong Kong, August 16, 2023

As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU and Dr. Donald Kwok Tung LI as independent non-executive Directors.